Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Molecular and Clinical Aspects of Aα Dysfibrinogenemia in 25 Patients from the Czech Republic

Eliska Ceznerova, MSc, Jana Stikarova, PhD, Pavla Roselova, MSc, Jirina Kaufmanova, MSc, Jiri Suttnar, PhD, Jan Louzil, MD, Roman Kotlin, PhD, Peter Salaj, MD, Jan E. Dyr, prof. PhDMSc. DSc.

Blood (2018) 132 (Supplement 1): 5046.

https://doi.org/10.1182/blood-2018-99-118254

Published: 2018

Journal Articles

Dysfibrinogenemias Affecting Platelet Aggregation

Roman Kotlín, PhD, Alzbeta Hlavackova, PhD, Ondrej Pastva, MSc., Jiri Suttnar, PhD, MSc., Jana Stikarova, PhD MSc, Eliska Ceznerova, MSc., Jan Louzil, MD, Peter Salaj, MD, Jan E. Dyr, prof. PhD MSc. DSc.

Blood (2017) 130 (Supplement 1): 1082.

https://doi.org/10.1182/blood.V130.Suppl_1.1082.1082

Published: 2017

Journal Articles

Measurable Amount of Active Thrombin Is Bound to Circulating D-Dimers. Is There Any Impact on Diagnosis and Pathophysiology of Thrombosis?

Jan E. Dyr, prof., PhD, MSc., DSc., Jana Stikarova, PhD, MSc., Jiri Suttnar, PhD, MSc., Katerina Kuzelova, PhD, Pavel Sacha, PhD, MSc., Ondrej Kucerka, MD, Jan Louzil, MD, Jaroslav Cermak, MD PhD, Petr Soukup, MD, Peter Salaj, MD, Martin Hajsl, MD, Martin Maly, MD PhD, Roman Kotlin, PhD, MSc.

Blood (2016) 128 (22): 2570.

https://doi.org/10.1182/blood.V128.22.2570.2570

Published: 2016

Journal Articles

Four Cases of Aaplha Dysfibrinogenemia in Childhood

Roman Kotlín, PhD, MSc., Eliška Ceznerova, MSc., Stikarová Jana, PhD, MSc., Alzbeta Hlavackova, PhD, MSc., Ondrej Pastva, MSc, Jiri Suttnar, PhD, MSc., Peter Salaj, MD, Jaroslav Cermak, MD PhD, Jan E. Dyr, prof., PhD, MSc., DSc.

Blood (2015) 126 (23): 4697.

https://doi.org/10.1182/blood.V126.23.4697.4697

Published: 2015

Journal Articles

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Amy D. Shapiro, MD, Ellis J. Neufeld, MD, PhD, Victor S. Blanchette, MD, FRCPC, Hervé Chambost, MD, PhD, Peter Salaj, MD, Robert Z. Gut, MD, PhD, David L. Cooper, MD, MBA

Blood (2011) 118 (21): 3316.

https://doi.org/10.1182/blood.V118.21.3316.3316

Published: 2011

NARROW

Molecular and Clinical Aspects of Aα Dysfibrinogenemia in 25 Patients from the Czech Republic

Dysfibrinogenemias Affecting Platelet Aggregation

Measurable Amount of Active Thrombin Is Bound to Circulating D-Dimers. Is There Any Impact on Diagnosis and Pathophysiology of Thrombosis?

Four Cases of Aaplha Dysfibrinogenemia in Childhood

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Email alerts

ASH Publications

American Society of Hematology

Molecular and Clinical Aspects of Aα Dysfibrinogenemia in 25 Patients from the Czech Republic

Dysfibrinogenemias Affecting Platelet Aggregation

Measurable Amount of Active Thrombin Is Bound to Circulating D-Dimers. Is There Any Impact on Diagnosis and Pathophysiology of Thrombosis?

Four Cases of Aaplha Dysfibrinogenemia in Childhood

Safety of Recombinant Activated Factor VII (rFVIIa) in Patients with Congenital Hemophilia with Inhibitors: Overall Dose Exposure and Intervals Following >240 Mcg/Kg Doses Across Trial, Registry and Diary Studies,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only